Searle launches Ostegem OD & M-Folate OD in Canada

November 17, 2025 (MLN): In a significant stride toward global expansion, The Searle Company Limited, one of Pakistan’s leading pharmaceutical manufacturers, has launched Ostegem OD and M-Folate OD in Canada, with availability confirmed across multiple pharmacies in the Greater Toronto Area (GTA).

The development was officially disclosed through the company’s verified Facebook, Instagram, and LinkedIn pages, making it the latest addition to Searle’s growing international portfolio.

Canada, with its stringent regulatory standards and robust healthcare infrastructure, represents an important step in Searle’s ambition to position itself among globally competitive pharmaceutical exporters.

Ostegem OD is positioned as a comprehensive bone-health formulation containing calcium, Vitamin D3, and Vitamin K2, nutrients widely prescribed in North American markets for bone density, fracture prevention, and overall skeletal support.

M-Folate OD, meanwhile, addresses folate deficiency through a bio-active methylated form of folate, making it suitable for individuals requiring improved folate metabolism, including pregnant women and patients with absorption issues.

Folate supplements constitute a fast-growing segment in Canada, driven by rising awareness around maternal health and nutritional deficiencies.

With the Canadian population increasingly leaning toward preventative healthcare and evidence-based supplementation, both products align well with existing demand patterns.

The introduction of Searle’s products into Canada signals the company’s progress in navigating the complexities of international compliance, quality certifications, and distribution partnerships.

While the company has not publicly disclosed specifics regarding regulatory pathways or distribution agreements, the availability of its products at GTA pharmacies indicates successful onboarding through local supply chains.

Searle’s latest move reinforces its broader trend of internationalization.

The company already exports to several regions, and its annual reports have highlighted a defined strategy for expanding presence across Middle East, Africa, Southeast Asia, and North America.

The Canada launch adds momentum to that trajectory, positioning Searle to introduce additional products in the future, potentially.

The expansion is also a positive signal for Pakistan’s pharmaceutical export landscape, which has long aimed to gain stronger footholds in regulated markets.

Successful product availability in Canada could enhance investor confidence and open avenues for other domestic companies seeking similar pathways.

Copyright Mettis Link News